Yana Pikman
Co-Director, Hematologic Malignancy Program, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center · Mass General Brigham
Credentials: · ·
History
- Present
Hematologic Malignancy Program · Mass General Brigham
- 2007–2010
- 2003–2007
Research
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
PLoS Medicine · 2006 · First of 17 authors · 1,170 citations
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Blood · 2006 · 836 citations
Proceedings of the National Academy of Sciences of the United States of America · 2005 · 263 citations
26 papers
14 papers
12 papers
12 papers
6 papers
- IG
6 papers
6 papers · 3 as a fellow
- DG
5 papers
Grants
- 2018–2023
National Cancer Institute · K08
Contact PI · $885.6K · Dana-Farber Cancer Inst
Clinical trials
- 2021–2033
Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens
Principal investigator · Recruiting
Dana-Farber Cancer Institute
- 2016–2028
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
Principal investigator · Active not recruiting
Dana-Farber Cancer Institute